Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN +0.89%30 EV-to-EBITDA is -103.63 as of Jul. 23, 2026. GuruFocus rates XSWX:CURN with a GF Score™ of 30/100. The stock has 7 warning signs investors should review. Among 741 Drug Manufacturers companies, Curatis Holding AG ranks worse than 134952.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Curatis Holding AG's enterprise value is CHF116.79 Mil.
Curatis Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.13 Mil. Therefore, Curatis Holding AG's EV-to-EBITDA for today is -103.63.
The historical rank and industry rank for Curatis Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:CURN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -108.99 Med: -7.83 Max: -5.88
Current: -103.63
During the past 5 years, the highest EV-to-EBITDA of Curatis Holding AG was -5.88. The lowest was -108.99. And the median was -7.83.
XSWX:CURN's EV-to-EBITDA is ranked worse than 100% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.24
vs XSWX:CURN: -103.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Curatis Holding AG (XSWX:CURN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curatis Holding AG's PE Ratio (TTM) for today is calculated as:
Curatis Holding AG's share price for today is CHF22.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.284.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Curatis Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's EV-to-EBITDA falls into.
Curatis Holding AG's current Enterprise Value is CHF116.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a EV-to-EBITDA of -103.63 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Curatis Holding AG. According to the industry distribution chart, Curatis Holding AG ranks #999999 out of 741 companies in the Drug Manufacturers industry.
Is Curatis Holding AG's EV-to-EBITDA too high?
Curatis Holding AG's current EV-to-EBITDA is -103.63. Based on the distribution chart, Curatis Holding AG ranks #999999 out of 741 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curatis Holding AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #999999 out of 741 companies for EV-to-EBITDA. This places Curatis Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.24, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Curatis Holding AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current EV-to-EBITDA is -103.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current EV-to-EBITDA of -103.63. The current EV-to-EBITDA is -103.63. Curatis Holding AG's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current EV-to-EBITDA is -103.63 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
30GF Score
Get the complete analysis for XSWX:CURN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
